Benzoyl Peroxide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BENZAMYCIN | — | 1984-10-26 | fda.gov ↗ |
Trials 78 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06673641 | May → Sep 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05675501 | Jun 2020 → Jul 2021 | rosacea | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02709902 | Sep 2015 → Feb 2016 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02578043 | Apr → Aug 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769235 | Nov 2012 → Sep 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01742637 | Oct 2012 → Feb 2014 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769664 | Sep 2012 → Jun 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01132443 | May → Jun 2010 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03076320 | Mar 2017 → Jan 2019 | acne | University of Guadalajara | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07032649 | Jan 2026 → Jan 2027 expected | — | Greg Bew | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04892706 | Jun 2021 → Sep 2022 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03257202 | Sep 2017 → Jan 2018 | — | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT03122457 | Jan 2017 → Jul 2018 | actinic keratosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00713609 | Jun 2008 → Mar 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 324 trials | ||||||
| Phase 3 | NCT05536882 | May 2022 → Oct 2023 | molluscum contagiosum | University of Oklahoma | Withdrawn | No outcome recorded |
| Phase 3 | NCT04028401 | Jun 2020 → Jun 2029 expected | skin infection | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03761784 | Dec 2018 → Dec 2019 | acne | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03564145 | Sep 2018 → Nov 2019 | rosacea | Sol-Gel Technologies, Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03448939 | Jun 2018 → May 2019 | rosacea | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02932267 | Feb 2017 → Jan 2018 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT02651220 | Nov 2015 → Apr 2016 | acne | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02515305 | Jul 2015 → Apr 2016 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02465632 | Apr → Nov 2015 | acne | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02005666 | Nov 2013 → Sep 2016 | acne | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 3 | NCT01910064 | May 2013 → Aug 2014 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01788384 | Jul → Dec 2012 | acne | Watson Laboratories, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01796665 | Feb 2012 → Feb 2013 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT01474590 | Nov 2011 → Jul 2013 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01445301 | Sep 2011 → Aug 2012 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00891982 | Apr → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00687908 | Nov 2008 → Jul 2009 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00776919 | Oct 2008 → Sep 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00688064 | Aug 2008 → Feb 2009 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00869492 | Aug 2008 → Jun 2009 | acne | Marmara University | Unknown | No outcome recorded |
| Phase 3 | NCT00441415 | Feb → Oct 2007 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00422240 | Jun 2006 → Jul 2007 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00151541 | Feb → Jul 2005 | acne | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00446043 | Feb 2004 → May 2005 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT05676411 | Jun 2024 → Jul 2025 | periprosthetic joint infection | University of Missouri-Columbia | Withdrawn | No outcome recorded |
| Phase 4 | NCT06336629 | Nov 2023 → Jul 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05446402 | Jun 2022 → May 2023 | acne | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT04548349 | Apr 2021 → Aug 2022 | acne | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03849885 | Feb 2019 → Dec 2023 | osteoarthritis | Colorado Joint Replacement | Unknown | No outcome recorded |
| Phase 4 | NCT04021524 | Sep 2018 → May 2019 | acne | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03563365 | Jun 2018 → Mar 2021 | acne | Yardley Dermatology Associates | Terminated | No outcome recorded |
| Phase 4 | NCT02899000 | Jul 2016 → Mar 2017 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02735421 | May 2016 → Jun 2017 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02557399 | Oct → Dec 2015 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02589405 | Aug 2015 → Jan 2016 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02058628 | Feb → Sep 2014 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02052752 | Feb → May 2014 | skin disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01951417 | Oct 2013 → Mar 2014 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01504204 | Dec 2011 → Nov 2012 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT01448733 | Jul → Oct 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01260571 | Jan → Mar 2011 | — | Zurita Laboratorio Farmaceutico Ltda. | Unknown | No outcome recorded |
| Phase 4 | NCT01209949 | Oct 2010 → Jan 2011 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01149330 | Jul 2010 → Mar 2011 | acne | Galderma Brasil Ltda. | Completed | No outcome recorded |
| Phase 4 | NCT01706263 | Aug → Nov 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00952523 | Jul → Oct 2009 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00964366 | Jul → Aug 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00907101 | Jun → Jul 2009 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00919191 | Apr → May 2009 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00907257 | Feb → Sep 2009 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00671749 | Dec 2007 → Aug 2008 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00841776 | Aug 2007 → Nov 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00807014 | Nov 2006 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00658112 | Jul 2006 → May 2008 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00377000 | Nov 2005 → Mar 2006 | acne | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00160394 | Dec 2004 → Aug 2005 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT05355844 | May 2022 → May 2023 | rotator cuff syndrome, spondylosis | Hospital del Mar | Unknown | No outcome recorded |
| — | NCT05855629 | Feb 2022 → Jun 2023 | acne | Treatment and Diagnostic Center of Private Enterprise "Asklepiy" | Unknown | No outcome recorded |
| — | NCT03949751 | Nov 2018 → Apr 2020 | — | Balgrist University Hospital | Completed | No outcome recorded |
| — | NCT03573115 | Jan → Jul 2018 | acne | Merete Haedersdal | Completed | No outcome recorded |
| — | NCT02219776 | Sep 2015 → Jun 2021 | infectious disease | McLaren Health Care | Completed | No outcome recorded |
| — | NCT02510144 | Aug 2015 → Jul 2018 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT02192632 | Jan 2014 → Feb 2015 | acne | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00787943 | May 2008 → Jan 2009 | acne | Northwestern University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 39 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04206631 Comparator | Apr → Sep 2015 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT02595034 Comparator | Jan → Oct 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01428466 Comparator | Nov 2010 → Feb 2011 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01106807 Comparator | Apr → Sep 2010 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT01880320 Comparator | Jul 2013 → Mar 2014 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01915732 Comparator | Apr 2013 → Apr 2014 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01138514 Comparator | Oct 2009 → Oct 2010 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT01014689 Comparator | Aug 2009 → Apr 2010 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00883233 Comparator | Apr → Sep 2009 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00877409 Comparator | Apr → Jul 2009 | acne | Zurita Laboratorio Farmaceutico Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT00421993 Comparator | Oct 2006 → Oct 2007 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00664248 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00663286 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02716090 Background | ? → Nov 2015 | acne | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT04300010 Comparator | Oct 2020 → Jan 2021 | acne | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT04000347 Comparator | Jun 2019 → Apr 2022 | — | Mahidol University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03832647 Background | Feb 2019 → Feb 2020 | acne | Vichy Laboratoires | Completed | No outcome recorded |
| Phase 4 | NCT05096312 Comparator | Dec 2018 → Jul 2019 | acne | East Avenue Medical Center, Philippines | Completed | No outcome recorded |
| Phase 4 | NCT02731105 Comparator | Feb 2015 → Feb 2017 | acne | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01522456 Comparator | Apr → May 2012 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01422785 Comparator | Jul → Dec 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01231334 Comparator | Aug 2010 → Jun 2011 | acne | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01138735 Comparator | Jun 2010 → Aug 2011 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01188538 Comparator | Mar → Aug 2010 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01015638 Comparator | Aug → Sep 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00964223 Background | Jul → Nov 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00926367 Comparator | May → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00887484 Background | Feb → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00837213 Comparator | Aug 2007 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT03650881 Comparator | Aug 2018 → Feb 2020 | acne | NYU Langone Health | Withdrawn | No outcome recorded |
| — | NCT02698436 Comparator | Mar → Aug 2016 | acne | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| — | NCT01818167 Comparator | Jan 2013 → Dec 2014 | hidradenitis suppurativa | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT01472900 Comparator | Oct 2010 → Apr 2012 | acne | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01237821 Comparator | Oct 2010 → Aug 2011 | acne | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT01176955 Background | May 2009 → Aug 2010 | acne | Wake Forest University | Completed | No outcome recorded |
| — | NCT01052246 Comparator | Oct 2008 → Jun 2009 | acne | Laserklinik Karlsruhe | Completed | No outcome recorded |
| — | NCT01044264 Comparator | Dec 2007 → Sep 2008 | acne | Padagis LLC | Completed | No outcome recorded |
| — | NCT00558831 Comparator | Oct 2007 → Jan 2008 | acne | Northwestern University | Completed | No outcome recorded |
| — | NCT00624676 Comparator | Jan → Aug 2006 | acne | Cosmetique Active International | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S. tevapharm.com ↗ |
| 2017-07-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Epiduo® in the United States tevapharm.com ↗ |
Evidence & citations 75 cited values
Every value below carries the sentence it was read from. 126 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | benzoyl peroxide | “METHODS: This 16-week, two-center, investigator-blinded, randomized, parallel-group study evaluated the antimicrobial efficacy of clindamycin phosphate 1%/benzoyl peroxide 5%...” PMID 20214175 ↗ Feb 2010114“Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area...” NCT03076320 ↗ “OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 “Objective: Evaluate subject-reported outcomes after treatment with adapalene 0.3%/ benzoyl peroxide 2.5% gel (0.3% A/BPO) in subjects with SOC and moderate to severe acne vulgaris.” PMID 31251543 ↗ Jun 2019 “Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.” NCT02735421 ↗ “Clindamycin phosphate (CLIN) 1.2%/adapalene (ADAP) 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB) is the only triple-combination topical approved for acne.” PMID 40377868 ↗ May 2025 “gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily” NCT00160394 ↗ “Benzoyl peroxide has antimicrobial and anti inflammatory properties and is often considered an important component of acne treatment.” NCT01706263 ↗ “Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris” NCT01149330 ↗ “A new formulation of benzoyl peroxide (E-BPO cream, 5%) entraps benzoyl peroxide (BPO) in silica microcapsules.” PMID 37636253 ↗ Aug 2023 “Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets” NCT00688064 ↗ “Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.” NCT01522456 ↗ “Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)” NCT03761784 ↗ “fixed-combination adapalene plus benzoyl peroxide (A/BPO) is a first-line recommended acne therapy” PMID 28686776 ↗ Jun 2017 “Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.” NCT02557399 ↗ “Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week” NCT00883233 ↗ “Adapalene 0.1% / Benzoyl Peroxide (BPO) 2.5% Gel associated with Lymecycline 300mg Capsules” NCT01014689 ↗ “fixed dose combination of 0.3% adapalene with 2.5% benzoyl peroxide (A/BPO gel 0.3%/2.5%)” PMID 28686775 ↗ Jun 2017 “GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO” NCT01910064 ↗ “Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days” NCT00891982 ↗ “fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin” PMID 24934963 ↗ Oct 2014 “Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg” NCT01445301 ↗ “Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.” NCT01188538 ↗ “1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)” NCT05446402 ↗ “benzoyl peroxide gel 2.5% on face in the morning and afternoon” NCT04206631 ↗ “Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks” NCT01237821 ↗ “containing 3% benzoyl peroxide (BPO) and 1% clindamycin” NCT02058628 ↗ “Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)” NCT01951417 ↗ “microencapsulated benzoyl peroxide cream, 5%” PMID 37636251 ↗ Aug 2023 “Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel” NCT00441415 ↗ “5% benzoyl peroxide), applied once daily” NCT00807014 ↗ “100 per arm Adapalene/ Benzoyl Peroxide” NCT03832647 ↗ “Clindamycin 1% and Benzoyl Peroxide 5%” NCT01015638 ↗ “Adapalene, benzoyl peroxide” NCT02709902 ↗ |
| Known as | Acetoxyl 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acetoxyl 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acnecide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acnecide 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acnegel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acnegel fte | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Acnidazil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Anhydrous benzoyl peroxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benoxyl 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benoxyl 20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benoxyl 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzagel 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzagel 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of acanya | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of aktipak | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of benzaclin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of benzamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of cabtreo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of duac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of epiduo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of idp-126 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of onexton | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoyl peroxide component of twyneo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | benzoyl peroxide gel 4% | “Dapsone Topical Gel + benzoyl peroxide gel 4%” NCT00151541 ↗ |
| Known as | Benzoyl superoxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoylis peroxidum cum aqua | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Benzoylperoxid | “The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin” NCT03949751 ↗1“Adapalen 0,1% and Benzoylperoxid 2,5%” NCT02731105 ↗ |
| Known as | BPO | “The purpose of this study was to compare the efficacy of blue light therapy (BLT) and 5% topical benzoyl peroxide (BPO) gel in combination with standard chlorhexidine (CHX)...” PMID 34478863 ↗ Aug 202115“OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 “Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.” NCT02735421 ↗ “BACKGROUND: Skin care products (cleansers and moisturizers) to complement benzoyl peroxide (BPO) in the treatment of acne may improve treatment tolerability and adherence.” PMID 28678647 ↗ Jul 2017 “The current study will evaluate the efficacy and tolerability of MAXCLARITY II, an over the counter, topical benzoyl peroxide (BPO) product line, in subjects with acne.” NCT01706263 ↗ “Clindamycin phosphate (CLIN) 1.2%/adapalene (ADAP) 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB) is the only triple-combination topical approved for acne.” PMID 40377868 ↗ May 2025 “A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% recently has been developed for the treatment of acne vulgaris.” PMID 19746769 ↗ Aug 2009 “Topical tretinoin and benzoyl peroxide (BPO) are often prescribed in combination for the treatment of acne vulgaris” PMID 20677537 ↗ Jul 2010 “Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets” NCT00688064 ↗ “Adapalene 0.1% / Benzoyl Peroxide (BPO) 2.5% Gel associated with Lymecycline 300mg Capsules” NCT01014689 ↗ “GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO” NCT01910064 ↗ “clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)” NCT01132443 ↗ “containing 3% benzoyl peroxide (BPO) and 1% clindamycin” NCT02058628 ↗ “Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)” NCT01951417 ↗ “benzoyl peroxide (BPO) 5% gel” NCT01015638 ↗ “benzoyl peroxide (BPO)” NCT00926367 ↗ |
| Known as | Brevoxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Brevoxyl-4 | “A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)” NCT02510144 ↗ |
| Known as | Brevoxyl-8 | “A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)” NCT02510144 ↗ |
| Known as | Clearasil max 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Dermoxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Dry clear | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | E-928 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | E-BPO | “A new formulation of benzoyl peroxide (E-BPO cream, 5%) entraps benzoyl peroxide (BPO) in silica microcapsules.” PMID 37636253 ↗ Aug 20232“Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)” NCT03761784 ↗ “once-daily topical microencapsulated benzoyl peroxide (E-BPO) compared to vehicle cream” PMID 39148964 ↗ Aug 2024 |
| Known as | Encapsulated benzoyl peroxide (E-BPO) cream | “Encapsulated benzoyl peroxide (E-BPO) cream” NCT03448939 ↗ |
| Known as | Epiduo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02192632 ↗ |
| Known as | Epsolay | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Gppe lotio gel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Hydrous benzoyl peroxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Ins no.928 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Ins-928 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Mediclear | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Mediclear acne 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Mediclear acne 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Nericur | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | NSC-671 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | NSC-675 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Oxy-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Oxy-10 cover-up | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Oxy-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 10 acnegel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 10 aquagel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 2.5 aquagel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 5 acnegel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl 5 aquagel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl crm 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl lot 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Panoxyl lot 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Quinoderm 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Quinoped | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Theraderm 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Theraderm 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Topex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Ultra clearasil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Valderma | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Known as | Vanair | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200370 ↗ |
| Action | Inhibit | “the fixed-dose combination gel containing adapalene 0.1% and benzoyl peroxide 2.5% effectively inhibited both antibiotic-susceptible and antibiotic-resistant Propionibacterium acnes.” PMID 21607190 ↗ May 2011 |
| Modality | Other / unclassified | “and an antimicrobial (benzoyl peroxide 2.5%)” PMID 21607190 ↗ May 2011 |
| Route | Topical | “Dapsone Topical Gel + benzoyl peroxide gel 4%” NCT00151541 ↗ |